Hoe verhoudt A006280's PS Ratio zich tot zijn concurrenten?

A006280 is good value based on its Price-To-Sales Ratio (1.1x) compared to the peer average (30.6x).

Hoe verhoudt A006280's PS Ratio zich tot andere bedrijven in de KR Biotechs industrie?

A006280 is good value based on its Price-To-Sales Ratio (1.1x) compared to the KR Biotechs industry average (9.8x).

Wat is A006280's PS Ratio vergeleken met zijn Fair PS Ratio? Dit is de verwachte PS Ratio, rekening houdend met de verwachte winstgroei van het bedrijf, winstmarges en andere risicofactoren.

A006280 is good value based on its Price-To-Sales Ratio (1.1x) compared to the estimated Fair Price-To-Sales Ratio (2.5x).

Wat is de reële prijs van A006280 als we kijken naar de toekomstige kasstromen? Voor deze schatting gebruiken we een Discounted Cash Flow-model.

A006280 (₩162500) is trading above our estimate of [[fair value]] (₩38285.61)

Wat is de 12-maandsprognose van de analisten en hebben we enig statistisch vertrouwen in het consensuskoersdoel?

Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

GC Biopharma (KOSE:A006280) - Aandelenkoers, Nieuws & Analyse

A006280 Overzicht aandelen

GC Biopharma Corp., een biofarmaceutisch bedrijf, ontwikkelt en verkoopt farmaceutische medicijnen in Zuid-Korea en internationaal.

Over het bedrijf

A006280 fundamentele analyse
Sneeuwvlok Score
Waardering	4/6
Toekomstige groei	3/6
Prestaties in het verleden	0/6
Financiële gezondheid	2/6
Dividenden	0/6

Beloningen

Earnings are forecast to grow 102.28% per year

Trading at good value compared to peers and industry

Analysts in good agreement that stock price will rise by 23.1%

Risicoanalyse

Interest payments are not well covered by earnings

GC Biopharma Corp. Concurrenten

ABL Bio

KOSDAQ:A298380

₩1.7t

NatureCellLtd

KOSDAQ:A007390

₩1.4t

Hugel

KOSDAQ:A145020

₩2.9t

PharmaResearch

KOSDAQ:A214450

₩2.2t

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor GC Biopharma
Historische aandelenkoersen
Huidige aandelenkoers	₩162,500.00
52 Week Hoogtepunt	₩181,800.00
52 Week Laag	₩100,000.00
Bèta	1.03
11 maand verandering	7.69%
3 maanden verandering	15.33%
1 Jaar Verandering	57.92%
33 jaar verandering	-32.85%
5 jaar verandering	32.65%
Verandering sinds IPO	-45.40%

Recent nieuws en updates

Is GC Biopharma (KRX:006280) A Risky Investment?

Oct 17

Recent updates

GC Biopharma Corp.'s (KRX:006280) Business And Shares Still Trailing The Industry

Mar 08

We Think Green Cross (KRX:006280) Can Stay On Top Of Its Debt

May 02

Are Green Cross Corporation's (KRX:006280) Mixed Financials Driving The Negative Sentiment?

Mar 10

Shareholders Are Thrilled That The Green Cross (KRX:006280) Share Price Increased 268%

Feb 18

Green Cross (KRX:006280) Has A Somewhat Strained Balance Sheet

Jan 31

Calculating The Intrinsic Value Of Green Cross Corporation (KRX:006280)

Jan 14

What You Need To Know About Green Cross Corporation's (KRX:006280) Investor Composition

Dec 27

Green Cross Corporation's (KRX:006280) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?

Dec 09

Does Green Cross's (KRX:006280) Statutory Profit Adequately Reflect Its Underlying Profit?

Nov 21

Rendement voor aandeelhouders

	A006280	KR Biotechs	KR Markt
7D	-0.3%	-2.6%	-1.2%
1Y	57.9%	41.8%	4.8%

Rendement versus industrie: A006280 exceeded the KR Biotechs industry which returned 41.8% over the past year.

Rendement versus markt: A006280 exceeded the KR Market which returned 4.8% over the past year.

Prijsvolatiliteit

Is A006280's price volatile compared to industry and market?
A006280 volatility
A006280 Average Weekly Movement	8.5%
Biotechs Industry Average Movement	9.5%
Market Average Movement	6.7%
10% most volatile stocks in KR Market	12.2%
10% least volatile stocks in KR Market	3.5%

Stabiele aandelenkoers: A006280 has not had significant price volatility in the past 3 months compared to the KR market.

Volatiliteit in de loop van de tijd: A006280's weekly volatility (9%) has been stable over the past year.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1967	2,016	Il-Sup Huh	www.globalgreencross.com

GC Biopharma Corp., een biofarmaceutisch bedrijf, ontwikkelt en verkoopt farmaceutische geneesmiddelen in Zuid-Korea en internationaal. Het biedt receptvrije geneesmiddelen, zoals Acustop Cataplasma voor een pijnstillend en ontstekingsremmend effect; Kenhancer pleister voor ontstekingsremming; en Zenol Cool Type en Zenol Mild Hot Type geneesmiddelen voor ontstekingsremming en pijnverlichting. Het bedrijf biedt ook Albumin-GCC injectie (inj.) voor hypoalbuminemie en shock bij acute bloedingen, evenals lage synthese van albumine; Antitrombin-III (AT-III) inj.

GC Biopharma Corp. Samenvatting

Hoe verhouden de winst en inkomsten van GC Biopharma zich tot de beurswaarde?
A006280 fundamentele statistieken
Marktkapitalisatie	₩1.85t
Inkomsten(TTM)	-₩38.20b
Inkomsten(TTM)	₩1.62t

1.1x

P/S-verhouding

-48.6x

Koers/Winstverhouding

Is A006280 overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
A006280 resultatenrekening (TTM)
Inkomsten	₩1.62t
Kosten van inkomsten	₩1.16t
Brutowinst	₩457.90b
Overige uitgaven	₩496.09b
Inkomsten	-₩38.20b

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-3.35k
Brutomarge	28.29%
Nettowinstmarge	-2.36%
Schuld/Eigen Vermogen Verhouding	52.3%

Hoe presteerde A006280 op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

0.9%

Huidig dividendrendement

-45%

Uitbetalingsratio

A006280 Overzicht aandelen

Beloningen

Risicoanalyse

GC Biopharma Corp. Concurrenten

KOSDAQ:A298380

₩1.7t

KOSDAQ:A007390

₩1.4t

KOSDAQ:A145020

₩2.9t

KOSDAQ:A214450

₩2.2t

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Price target increased by 10% to ₩195,000

Now 21% overvalued after recent price rise

Is GC Biopharma (KRX:006280) A Risky Investment?

Price target increased by 11% to ₩188,333

GC Biopharma and Hanmi Pharmaceutical Receives IND Clearance for Phase 1/2 Clinical Trial from the U.S. FDA

Price target increased by 7.7% to ₩162,000

Recent updates

Price target increased by 10% to ₩195,000

Now 21% overvalued after recent price rise

Is GC Biopharma (KRX:006280) A Risky Investment?

Price target increased by 11% to ₩188,333

GC Biopharma and Hanmi Pharmaceutical Receives IND Clearance for Phase 1/2 Clinical Trial from the U.S. FDA

Price target increased by 7.7% to ₩162,000

There's No Escaping GC Biopharma Corp.'s (KRX:006280) Muted Revenues

Now 21% overvalued after recent price rise

A Look At The Fair Value Of GC Biopharma Corp. (KRX:006280)

New major risk - Financial position

Is GC Biopharma (KRX:006280) A Risky Investment?

Gc Biopharma and Novel Pharma Announce Sanfilippo Syndrome Treatment Obtains FDA IND Approval

GC Biopharma Corp.'s (KRX:006280) Business And Shares Still Trailing The Industry

Upcoming dividend of ₩1,750 per share at 1.4% yield

GC Biopharma Corp. Announces US FDA Approval for ALYGLO (Immune Globulin Intravenous, Human-Stwk) 10% Liquid for Adults with Primary Humoral Immunodeficiency (PI)

Consensus EPS estimates fall from profit to ₩269 loss

GC Biopharma Applies for MFDS Approval

Consensus EPS estimates fall from profit to ₩1,046 loss

Consensus EPS estimates fall by 31%

Now 21% undervalued after recent price drop

Consensus EPS estimates increase by 18%, revenue downgraded

GC Biopharma's "GC FLU" Obtains Vaccine Approval in Egypt

Consensus EPS estimates fall by 38%

Consensus EPS estimates increase by 11%

GC Biopharma Receives a Business License for the Construction of a Plasma Fractionation Plant and Technology Transfer in Indonesia

Full year 2022 earnings: EPS exceeds analyst expectations

Price target decreased to ₩176,750

Upcoming dividend of ₩2,000 per share

Price target decreased to ₩191,222

Less than half of directors are independent

Now 21% undervalued after recent price drop

Price target decreased to ₩208,875

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analyst expectations

Less than half of directors are independent

Price target decreased to ₩254,400

GC Pharma Receives Complete Response Letter From the U.S. FDA For 'ALYGLO'

Investor sentiment improved over the past week

Price target decreased to ₩310,167

Consensus forecasts updated

Upcoming dividend of ₩1,500 per share

Price target decreased to ₩418,333

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

GC Pharma Announces Publication of Results From Phase III Clinical Trial of ‘GC5107’ Immune Globulin in Frontiers in Immunology

Price target increased to ₩434,000

Price target increased to ₩383,000

First quarter 2021 earnings released: EPS ₩1,293 (vs ₩368 loss in 1Q 2020)

US FDA Accepts GC Pharma’s Biologics License Application for Immune Globulin 'GC5107'

We Think Green Cross (KRX:006280) Can Stay On Top Of Its Debt

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS ₩7,087 (vs ₩118 in FY 2019)

Are Green Cross Corporation's (KRX:006280) Mixed Financials Driving The Negative Sentiment?

New 90-day low: ₩333,500

GC Pharma Finalises Agreement with Moderna and the Government of the Republic of Korea for Covid-19 Vaccines Distribution

GC Pharma Submits Biologics License Application to US FDA for Immune Globulin 'GC5107'

Shareholders Are Thrilled That The Green Cross (KRX:006280) Share Price Increased 268%

Green Cross Corporation, Annual General Meeting, Mar 25, 2021

Green Cross (KRX:006280) Has A Somewhat Strained Balance Sheet